Is attributing smoking to genetic causes associated with a reduced probability of quit attempt success? A cohort study

Addiction

Volumn 102, Issue 10, 2007, Pages 1657-1664

  Wright, Alison J ^a   Aveyard, Paul ^b,c   Guo, Boliang ^b   Murphy, Michael ^c   Brown, Karen ^c   Marteau, Theresa M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Behavioural influences; Causal attributions; Genetic testing; Perceived control; Pharmacogenetic intervention; Smoking cessation

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PRIMARY MEDICAL CARE; SMOKING; SMOKING CESSATION; UNITED KINGDOM;

ADULT; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HEALTH PROMOTION; HUMANS; MALE; SMOKING; SMOKING CESSATION;

EID: 34548583181     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2007.01937.x     Document Type: Article

References (21)

1. Lerman C., Wileyto E. P., Patterson F., Rukstalis M., Audrain-McGovern J., Restine S. et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 2004 4 : 184 92.
2. Lerman C., Jepson C., Wileyto E. P., Epstein L. H., Rukstalis M., Patterson F. et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials 10.1038/sj.npp.1300861. Neuropsychopharmacology 2006 31 : 231 42.
3. Swan G. E., Valdes A. M., Ring H. Z., Khroyan T. V., Jack L. M., Ton C. C. et al. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J 2005 5 : 21 9.
4. Munafo M. R., Shields A. E., Berrettini W., Patterson F., Lerman C. Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics 2005 6 : 211 23.
5. Leventhal H., Leventhal E. A., Contrada R. J. Self-regulation, health and behaviour: a perceptual-cognitive approach. Psychol Health 1998 13 : 717 33.
6. Marteau T. M., Weinman J. Self-regulation and the behavioural response to DNA risk information: a theoretical analysis and framework for future research. Soc Sci Med 2006 62 : 1360 8.
7. Shiloh S., Rashuk-Rosenthal D., Benyamini Y. Illness causal attributions. An exploratory study of their structure and associations with other illness cognitions and perceptions of control. J Behav Med 2002 25 : 373 94.
8. Godin G., Kok G. The theory of planned behavior: a review of its applications to health-related behaviors. Am J Health Promot 1996 11 : 87 98.
9. Conner M., Norman P. Predicting Health Behaviour, 2nd edn. Maidenhead : Open University Press 2005.
10. Phelan J. C., Yang L. H., Cruz-Rojas R. Effects of attributing serious mental illnesses to genetic causes on orientations to treatment. Psychiatr Serv 2006 57 : 382 7.
11. Marteau T., Senior V., Humphries S. E., Bobrow M., Cranston T., Crook M. A. et al. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am J Med Genet 2004 128A : 285 93.
12. Wright A. J., Weinman J., Marteau T. M. The impact of learning of a genetic predisposition to nicotine dependence: an analogue study. Tob Control 2003 12 : 227 30.
13. Aveyard P., Brown K., Saunders C., Alexander A., Johnstone E., Munafo M. et al. A randomised controlled trial of weekly versus basic smoking cessation support in primary care. Thorax 2007 DOI: 10.1136/thx.2006.071837.
14. Velicer W. F., DiClimente C. C., Rossi J., Prochaska J. O. Relapse situations and self-efficacy: an integrative model. Addict Behav 1990 15 : 271 83.
15. Heatherton T. F., Kozlowski L. T., Frecker R. C., Fagerstrom K. O. The fagerstrom test for nicotine dependence: a revision of the fagerstrom tolerance questionnaire. Br J Addict 1991 86 : 1119 27.
16. SRNT Sub-Committee on Biochemical Verification. Biochemical verfication of tobacco use and cessation. Nicotine Tob Res 2002 4 : 149 59.
17. Muthen B. O., Muthen L. K. Mplus User's Guide. Los Angeles, CA : Muthen & Muthen 2006.
18. Staring A. B. P., Breteler M. H. M. Decline in smoking cessation rate associated with high self-efficacy scores. Prev Med 2004 39 : 863 8.
19. Segan C. J., Borland R., Greenwood K. M. Do transtheoretical model measures predict the transition from preparation to action in smoking cessation? Psychol Health 2002 17 : 417 35.
20. Velicer W. F., Norman G. J., Fava J. L., Prochaska J. O. Testing 40 predictions from the transtheoretical model. Addict Behav 1999 24 : 455 69.
21. Carlson LE, Taenzer P, Koopmans J, Casebeer A. Predictive value of aspects of the Transtheoretical Model on smoking cessation in a community-based, large-group cognitive behavioral program. Addict Behav 2003 28 : 725 40.